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Abstract 
Natriuretic peptides (NPs) play a key role in cardiovascular homeostasis, counteracting the 
deleterious effects of volume and pressure overload and activating antibrotic and antihypertrophic 
pathways in the heart. N-terminal B-type NP (NT-proBNP) also is a promising biomarker of global 
cardiovascular risk in the general population, and there is increasing interest on its potential use in 
diabetic patients for screening of silent cardiovascular abnormalities, cardiovascular risk 
stratification, and guided intervention. Recently, both atrial NP (ANP) and B-type NP (BNP) have 
emerged as key mediators in the control of metabolic processes including the heart in the network 
of organs that regulate energy usage and metabolism. Epidemiological studies have shown that 
ANP and BNP are reduced in people with obesity, insulin resistance, and diabetes, and this 
deficiency may contribute to enhance their global cardiovascular risk. Moreover, ANP and BNP 
have receptors in the adipose tissue, enhance lipolysis and energy expenditure, and modulate 
adipokine release and food intake. Therefore, low ANP and BNP levels may be not only a 
consequence but also a cause of obesity, and recent prospective studies have shown that low 
levels of NT-proBNP and midregional proANP (MR-proANP) are a strong predictor of type 2 
diabetes onset. Whether ANP and BNP supplementation may result in either cardiovascular or 
metabolic benefits in humans remains, however, to be established. 
  
3 
 
Introduction 
Natriuretic peptides (NPs) have gained great interest as indicators of the state of cardiovascular 
health across the spectrum of cardiovascular diseases (CVD) in diabetic subjects (1–4). Recently, 
NPs also have emerged as key mediators in the control of metabolic processes (5) and have been 
implicated in the development of diabetes (6,7), shifting current paradigms and opening novel 
avenues in diabetes research. This review will summarize new findings in the field and discuss 
their potential clinical relevance. 
NPs and Their Receptors 
NPs are a family of genetically distinct and structurally related peptides, including atrial NP (ANP), 
B-type NP (BNP), and C-type NP (CNP). They share a similar structural conformation, characterized 
by a peptide ring with a cysteine bridge, which is well preserved throughout evolution, being the 
portion of the chain that binds to the receptor. ANP and BNP are predominantly secreted by 
cardiomyocytes, whereas CNP is mainly produced by the central nervous system, the endothelium, 
the bone, and the reproductive system (8–11). 
Human NP genes encode for long inactive peptides that are processed to active peptides and 
equimolar concentrations of inactive fragments, which have a longer plasma half-life and are thus 
more suitable biomarkers for clinical use (12). ProANP is processed into active ANP and inactive 
fragments (N-terminal BNP [NT-proBNP] and midregional proANP [MR-proANP]) predominantly by 
the enzyme corin (13). ProBNP, which is often posttranslationally O-glycosylated in the N-terminal 
region, is cleaved into active BNP and the inactive fragment NT-proBNP by corin and furin (9). 
ProBNP can be released into the bloodstream prior to processing (14), but has six- to eightfold 
lower activity than BNP. The CNP gene encodes for a 126 prepropeptide that contains the two 
active forms of CNP (CNP-22 and CNP-53) and the inactive NT-proCNP fragment (11). 
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The most important factor governing ANP secretion is mechanical stretching of the atria. ANP is 
stored in secretory granules and stretching induces both secretion of previously synthesized ANP 
and increased ANP gene transcription. Stress of the ventricular wall due to volume and/or 
pressure overload also is the main inducer of BNP transcription (10,15). Circulating BNP and NT-
proBNP levels are quite low in the normal state but rise in pathophysiological conditions 
characterized by fluid retention, such as heart failure (HF) (16). In addition, hypoxia-response 
elements are present in the promoter region of the BNP gene and both myocardial ischemia and 
hypoxia are potent BNP inducers (17). This explains why high BNP levels are found in acute 
coronary syndrome or during exercise-induced ischemia despite the absence of ventricular 
dilatation. Finally, ANP and BNP secretion can be modulated by humoral factors, including 
endothelin-1, angiotensin II, sex steroids and thyroid hormones, glucocorticoids, and inflammatory 
cytokines (tumor necrosis factor-α [TNF-α], interleukin [IL]-1, IL-6) (8–10,18). CNP expression is 
regulated by transforming growth factor-β1 (TGF-β1) and other growth factors in a cell- and 
tissue-specific manner. In the endothelium, TGF-β, TNF-α, and IL-1 enhance CNP expression, 
whereas platelet-derived growth factor–BB is the major CNP inducer in vascular smooth muscle 
cells (11). 
ANP and BNP plasma levels are higher in women than in men and increase with age (19). There is 
preliminary evidence that estrogens induce ANP and BNP production, whereas androgens 
suppress it; this may account for the sex differences in plasma concentrations (20). Plasma CNP 
levels are greater in men than in women, decline from adolescent to the fifth decade, and tend to 
increase thereafter, particularly in men (21). This is likely because both testosterone and growth 
hormone are potent CNP inducers (11). 
NPs bind to high-affinity transmembrane NP receptors (NPR)-A, NPR-B, NPR-C that share a 
relatively common molecular configuration. NPR-C binds to all three peptides with similar affinity, 
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whereas NPR-A and NPR-B differ in ligand specificity (NPR-A: ANP>BNP>>CNP; NPR-B: 
CNP>>ANP≥BNP); this, together with NPR tissue distribution, affects NP peripheral activity. 
Binding to both NPR-A and NPR-B causes a conformational change in the receptor molecule that, 
in turn, activates particulate guanylyl-cyclase and increases intracellular cGMP that represents a 
second messenger critical to NP activity. By contrast, binding to NPR-C results in NP internalization 
and enzymatic degradation, and NPR-C plays a key role in NP clearance (9,22) (Fig. 1). In addition 
to undergoing receptor-mediated degradation, NPs can be degraded by extracellular proteases, 
including neutral endopeptidase (NEP) and insulin-degrading enzyme (8,23). Moreover, cleavage 
of two N-terminal amino acids from BNP by the enzyme dipeptidyl peptidase-4 (DPP-4) yields 
BNP3–32, which retains the physiologic effects of BNP on the heart but has lower activity on both 
the kidney and the vessel wall (24). Other aminopeptidases can further digest the N-terminal 
region of BNP and BNP3–32, leading to formation of breakdown products (junk-BNP) of unclear 
biological significance (25) (Fig. 2). Biological Actions of NPs and Metabolism 
Both ANP and BNP are important in maintaining cardiovascular homeostasis and counteracting the 
deleterious effects of volume and pressure overload. Indeed, they act on the kidney to promote 
diuresis and natriuresis, induce vasodilation, and protect the heart from high preload and 
afterload pressures, which can result in hypertrophy and fibrosis by activating antibrotic and 
antihypertrophic pathways (26–28). In addition, ANP and BNP reduce the sympathetic tone and 
suppress both renin and aldosterone secretion; therefore, they not only counterbalance but also 
lower the activity of systems with opposing renal and cardiovascular effects (29). Endothelial CNP, 
which is known to induce vasorelaxation by hyperpolarization of underlying vascular muscle cells, 
is a potential endothelium-derived hyperpolarizing factor, participating in the paracrine action of 
other endothelial vasorelaxant mediators, such as nitric oxide (NO) and prostacyclin (11). 
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Our understanding of the physiology of the NP system has dramatically increased in the past 
decades, and today the key role of NPs in cardiovascular homeostasis is well established (see 
previous reviews [26–29]); however, emerging evidence suggests that the effects of NPs extend 
beyond the cardiovascular system. As detailed below, NPR are expressed in human adipose tissue, 
and NPs can stimulate lipolysis, promote browning of adipocytes, and also may modulate 
adipokine secretion and food intake (5,30–35). This previously unsuspected role of NPs in the 
regulation of metabolism is important as it raises the possibility that the heart belongs to the 
network of endocrine organs that regulate energy usage and metabolism. Furthermore, it may 
provide new targets for therapeutic intervention in the fight against obesity and insulin resistance. 
The lipolytic effect of ANP was first shown almost 20 years ago in physiological studies in humans. 
Intravenous infusion of ANP acutely increases plasma concentrations of both glycerol and free 
fatty acids (FFA) (36). Furthermore, ANP infusion in human subcutaneous abdominal adipose 
tissue induces lipolysis and increases local blood flow, resulting in enhanced lipid mobilization (37). 
Elegant studies performed in humans suggest that FFA mobilized in response to ANP may undergo 
mitochondrial oxidation in the liver, the skeletal muscle, and the adipose tissue itself (37–39). In 
vitro studies on adipocytes have partially clarified the underlying mechanism of NP lipolytic 
activity. Activation of the NPR-A receptor induces a rise in cGMP levels, followed by activation of 
protein kinase G (PKG). PKG, in turn, phosphorylates perilipin, and this induces a physical 
alteration of the lipid droplet surface that facilitates activation of both adipose triglyceride lipase 
and hormone-sensitive lipase, thus triggering lipolysis (35). The clearance receptor NPR-C reduces 
NPR-A–mediated lipolysis by lowering local NP bioavailability. Indeed, rodents, which express NPR-
C at high levels on adipocytes, have a blunted lipolytic response to NPs, and NPR-C deletion 
rescues their responsiveness (32). 
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A recent breakthrough in our understanding of role of NP on fat tissue metabolism has been the 
demonstration that in adipocytes NPR-A activation induces transcription of genes enhancing 
energy expenditure and heat production (adipocyte browning) (32). The most important gene 
encodes the mitochondrial transporter uncoupling protein 1 (UCP1) that enables the separation of 
lipid oxidation from ATP production, allowing the conversion of nutritional energy to heat. NPR-A 
activation elicits this response by increasing p38α signaling and phosphorylation of ATF2, directly 
increasing PPARγ coactivator-1α [PGC-1α]) and UCP1 transcription. PGC-1α and UCP-1 promote 
mitochondrial biogenesis and both coupled and uncoupled respiration, and this results in 
enhanced energy expenditure thereby limiting white fat mass expansion. In line with these 
findings, NPR-A knockout mice have an increased fat mass, whereas BNP infusion results in 
enhanced energy expenditure in mice (32). 
NPs also have a direct effect on the skeletal muscle, the major site of fuel oxidation and energy 
expenditure. Transgenic mice overexpressing BNP and fed with a high-fat diet display higher 
expression of mitochondrial oxidative genes in skeletal muscle (40). Furthermore, cultured human 
skeletal muscle myotubes respond to both ANP and BNP with a significant increase in 
mitochondrial fat oxidative capacity through transcriptional activation of PGC-1α and subsequent 
induction of oxidative phosphorylation (OXPHOS) genes and mitochondrial respiration (39). ANP 
also induces energy uncoupling, possibly via overexpression of UCP-3 and adenine nucleotide 
translocase 1, which accounts for 50% of basal (noninduced) proton leak (41). Notably, an 
upregulation of NPR-A, PGC-1α, and OXPHOS genes is observed in the skeletal muscle of obese 
subjects in response to an aerobic exercise training program, suggesting that some of the 
metabolic adaptations of skeletal muscle in response to chronic exercise may be mediated by ANP 
and BNP (39). 
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Data on the interplay between the NP system and cytokines released by the fat tissue are still 
limited. However, in vitro in human adipocytes, ANP inhibits leptin release and both ANP and BNP 
enhance adiponectin secretion via NPR-A (33). In addition, in adipose tissue explants, ANP reduces 
IL-6, TNF-α, MCP-1, and leptin secretion (35). Finally, ANP infusion enhances adiponectin plasma 
levels in humans (42). Collectively, these findings suggest that NPR-A activation may modulate 
adipokine secretion and has a beneficial effect on low-grade inflammation of the adipose tissue 
and thus insulin resistance. 
Recent studies suggest that NPs are involved in food intake control. A study performed in healthy 
fasting volunteers has shown that BNP infusion decreases hunger and increases satiety, possibly 
by lowering circulating ghrelin levels (34). Ghrelin also has direct cardiovascular effects (43), and 
this supports the existence of a bidirectional heart–gut cross talk. In addition, the high expression 
of NPR-B, the main CNP receptor, in the arcuate nucleus of the hypothalamus suggests a role of 
CNP in the control of food intake. Consistently, a recent experimental study has shown that central 
administration of CNP reduces food intake and body weight, partially through activation of the 
hypothalamic melanocortin pathway, which also is engaged by leptin and serotonin (44). Recently, 
Kim et al. (45) have described an entirely new mechanism in the control of ANP release from the 
heart by the gut-released hormone GLP-1, revealing a new gut–heart connection. Activation of 
GLP-1 receptors in the atrial myocardium induces ANP secretion, resulting in vasodilation, 
natriuresis, and reduced blood pressure. Therefore, an increase in nutrients after a meal triggers a 
gut-mediated response, leading not only to effective regulation of insulin and glucagon release 
through a direct GLP-1 effect but also to indirect metabolic and hemodynamic changes mediated 
by ANP. ANP-induced vasodilation may be advantageous in this setting as it may promote an 
increased blood supply to the gut and adipose tissue, thus resulting in better absorption and 
distribution of nutrients (45,46). 
9 
 
The key role of insulin in metabolism has prompted studies on the potential interplay between 
NPs and β-cells. In vitro ANP induces insulin secretion in an NPR-A–dependent manner by 
increasing Ca2+ influx through blockade of ATP-sensitive K+ channels. Furthermore, ANP increases 
the insulin content of isolated islets, and NPR-A knockout mice have lower insulin levels in freshly 
isolated islets, reduced β-cell mass, and higher fasting blood glucose levels (47). In keeping with 
these data, ANP infusion enhances insulin secretion in humans in the fasted state and in response 
to a meal test (37,48). 
Only a few studies have assessed the effect of NP infusion on glucose homeostasis. In fasting 
healthy men, an acute high-dose ANP infusion induces a modest increase in blood glucose that is 
likely due to enhanced FFA mobilization leading to increased gluconeogenesis (38). Short-term 
BNP infusion in healthy volunteers during an intravenous glucose tolerance test reduces the rise in 
blood glucose levels as compared with saline. This occurs without changes in insulin secretion and 
sensitivity and probably results from enhanced glucose volume distribution (49). These 
physiological studies do not, however, address the far more relevant issue of the long-term effects 
of chronic NP treatment on glucose metabolism. This has not yet been investigated in humans; 
however, a recent study in db/db mice has shown that chronic BNP infusion induces a significant 
reduction in blood glucose levels (50). 
Obviously there is much additional work to be done in both basic and clinical research to fully 
understand the function of the NP system in metabolic processes. However, emerging evidence 
indicating that NPs are the mediators of a novel “heart-adipose axis” has opened the way to an 
entirely novel and exciting area of research with potentially high clinical impact. 
NPs and Obesity, Diabetes, and Diabetes Complications 
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Obesity 
Obesity is associated with decreased circulating levels of ANP and BNP, and a negative linear 
relationship between BMI and NP plasma values has been consistently reported in epidemiological 
studies (5,35,51). Conversely, weight loss increases NT-proBNP levels (52). There also is evidence 
that a reduction in NP levels is associated to a less favorable adipose tissue distribution profile. 
Recent data from the Dallas Heart Study show that both BNP and NT-proBNP are inversely 
associated with visceral and liver fat and positively associated with lower glutofemoral body fat, 
independent of confounders including insulin resistance (53). 
Central obesity is a key feature of the metabolic syndrome (MetS); it is, however, still matter of 
debate if BNP and NT-proBNP levels are reduced in MetS, with studies reporting either lower or 
unchanged values. This is likely due to differences among examined populations in the relative 
frequencies of MetS components with opposite effects on BNP. Consistently, a recent longitudinal 
study performed on 3,019 African Americans has shown that both lower and higher BNP levels 
were predictors of incident MetS in a nonlinear U-shape relationship, likely a reflection of lower 
BNP relation to obesity and higher BNP relation to blood pressure (54). 
The cause of the relative ANP and BNP deficiency seen in obesity (natriuretic handicap) is poorly 
understood, but it is of clinical relevance as it may expose obese patients to enhanced 
cardiovascular risk and represent a potential mechanism behind the frequent clustering of obesity 
and hypertension. Almost two decades ago, researchers interested in the relationship between 
obesity and hypertension noted that levels of the clearance NPR-C were markedly elevated in 
obese subjects. The underlying mechanism remains elusive; however, food intake and insulin 
resistance are likely involved as adipose tissue NPR-C expression is increased by a high-fat diet, 
correlates with fasting insulin, and is reduced by pharmacological strategies improving insulin 
sensitivity (5,40). Regardless of the mechanism, the observation that NPR-C is overexpressed in 
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obese subjects fueled speculation that increased NP clearance could explain the “natriuretic 
handicap.” However, both NT-proBNP and NT-proANP, which are not cleared by NPR-C, show a 
similar inverse relationship with BMI, making this hypothesis less likely. In addition, recent data 
indicate that NPs are mainly cleared by NEP. 
Alternatively, ANP and BNP levels may be reduced in obesity because of a lower synthesis and/or 
release from the heart. In keeping with this hypothesis, cardiac mRNA expression of both ANP and 
BNP is reduced in obese Zucker fatty rats and db/db mice (50,55). Data in humans are limited; 
however, a study in subjects who underwent cardiac catheterization has shown that cardiac BNP 
release is inversely and independently related to BMI (56). Obese individuals may be prone to a 
relative NP deficiency, stemming from suppressive effects of circulating androgens on ANP and 
BNP synthesis (57) and possibly from the deleterious systemic and local effects of cardiac ectopic 
fat on NP synthesis and release (58,59). Consistently, downregulation of cardiac ANP and BNP 
expression is paralleled by a rise in cardiac triglycerides content in animal models of obesity, and 
oleic acid reduces ANP mRNA levels in cultured cardiomyocytes (60). 
On the other hand, the recently discovered effects of NPs on metabolism and energy expenditure 
raise the possibility that NP deficiency may directly contribute to the development and worsening 
of obesity and dysmetabolism. Indeed, in obese and insulin-resistant subjects, reduced ANP and 
BNP levels and upregulation of the clearance NPR-C in the adipose tissue may hamper the ability 
of the local NP system to enhance lipolysis and energy expenditure (5). In keeping with this 
hypothesis, targeted deletion of the NPR-C gene in rodents results in a lean phenotype, transgenic 
BNP mice fed with a high-fat diet are protected from obesity and insulin resistance, and chronic 
BNP infusion improves the metabolic profile of db/db mice, including a reduction in fat content 
(32,40,50). 
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Diabetes 
Growing evidence of a role of NPs in obesity and insulin resistance raises the question of whether 
NP deficiency is implicated in the development of type 2 diabetes (T2D). Recently, two large and 
well-designed prospective studies have substantiated this hypothesis. In the Malmö Diet and 
Cancer Study (6), MR-ANP and NT-proBNP levels were measured in 1,828 nondiabetic individuals 
who subsequently underwent a 16-year follow-up exam, including an oral glucose tolerance test. 
Results showed that low MR-ANP plasma levels predict development of future diabetes. After full 
adjustment, the odds ratio for incident diabetes in the bottom compared with the top quartile of 
MR-ANP was 1.65 (95% CI 1.08–2.51), independent of confounders. An inverse, but not 
statistically significant, association was found between NT-proBNP and diabetes risk. In the same 
cohort, the variant rs5068 within the ANP gene, which results in enhanced plasma ANP levels, was 
associated with a 12% reduced adjusted-risk of incident diabetes (61). Furthermore, other studies 
have reported that the rs5068 variant is associated with lower BMI, waist circumference, and 
prevalence of obesity and MetS (62,63). 
In the longitudinal Atherosclerosis Risk in Communities Study (ARIC) (7), which examined 7,822 
nondiabetic individuals, with respect to NT-proBNP values in the highest quartile (>114 pg/mL), 
values in the lowest quartile (<31 pg/mL) were associated with higher risk of incident diabetes 
over a 12-year follow-up period, independent of confounders and risk factors (hazard ratio 0.75 
[95% CI 0.64–0.87]). A significant linear trend across quartiles also was evident, even after 
stratification by BMI (7). Furthermore, a common genetic BNP variant (rs198389), which results in 
a 20% increase in plasma BNP levels, was found to be associated with a 15% reduced risk of T2D 
(64). See Table 1 for a summary of human studies (6,7,61,64,65). Insight on the mechanisms 
whereby NP deficiency may enhance diabetes risk is still insufficient. In the Malmö and ARIC 
studies, the prospective relationship between MR-ANP and NT-proBNP and diabetes remained 
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significant after adjustment for insulin resistance, indicating that alternative mechanisms, such as 
NPR-A–induced energy expenditure, adiponectin secretion, and improved β-cell function, may be 
involved (Fig. 3). Regardless of the mechanism, the evidence that low NP levels are implicated in 
the development of diabetes together with the well-established role of low NPs in hypertension 
and CVD suggests that NP deficiency may be a link between the relevant clinical problem of shared 
propensity to diabetes, hypertension, and CVD. Moreover, it suggests that NT-proBNP and MR-
ANP may be used as biomarker for diabetes prediction. Further studies are, however, required to 
establish clinical relevance. Diabetes Complications 
Both BNP and NT-proBNP are well-established diagnostic and prognostic biomarkers of HF in both 
diabetic and nondiabetic subjects (16). Although BNP and NT-proBNP levels appear elevated in 
patients with HF, the fraction of active BNP is relatively small. Current assays cross-react with 
poorly active BNP-related peptides (proBNP, BNP3–32, junk-BNP) (Fig. 2), whose levels are 
increased in HF, and they thus overestimate plasma and serum BNP and NT-proBNP values (25). 
Altered cardiac processing of proBNP to BNP is a likely explanation for the rise in circulating 
proBNP levels in HF. Notably, a recent study in humans has shown that cardiac proBNP release 
was greater in patients with HF and that the only variable positively associated with enhanced 
proBNP secretion was diabetes (14). This suggests that HF, particularly in diabetes, affects either 
the expression and activity of proBNP cleaving enzymes or proBNP glycosylation, a modification 
that changes proBNP susceptibility to cleavage by furin, particularly when it occurs at Thr71 (25). 
On the other hand, studies in db/db mice suggest that both enhanced BNP3–32 formation and 
resistance to mechanisms of proBNP clearance from the circulation also may contribute to 
increase circulating BNP immunoreactivity in diabetes (50). 
BNP and NT-proBNP are not always reliable biomarkers for HF diagnosis as 30% of symptomatic HF 
patients with preserved ejection fraction (HFPEF) have normal BNP and NT-proBNP levels (66). 
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This is of relevance to diabetes as HFPEF prevalence is very high in T2D and the relative risk of 
cardiovascular death or HF hospitalization conferred by diabetes is significantly greater in HFPEF 
than in HF with reduced ejection fraction (HFREF) (67,68). Recently, studies performed on 
myocardial tissue from patients with HFPEF and left ventricular (LV) diastolic dysfunction have 
given new insight on the potential relationship between diabetes, HFPEF, and BNP. According to a 
novel proposed paradigm for the pathogenesis of HFPEF, a systemic inflammatory state induced 
by obesity, diabetes, and other comorbidities causes oxidative stress in the coronary microvascular 
endothelium, reducing myocardial NO bioavailability and leading to reduced PKG activity in 
cardiomyocytes, which therefore become stiff and hypertrophied (69). As BNP gene expression is 
regulated by diastolic LV wall stress, which is lower in HFPEF because of prevailing concentric LV 
remodeling, this is not compensated by an enhanced BNP production. Consistently, myocardial 
BNP expression is lower in patients with HFPEF than in those with HFREF (70). This raises the 
possibility that drugs increasing BNP levels may represent a novel therapeutic strategy in patients 
with HFPEF and the PARAGON-HF trial is under development to test this hypothesis. 
Besides HF, BNP and NT-proBNP can provide quantitative information about the state of 
cardiovascular health across the full spectrum of CVD, and there is increasing interest on their 
potential role as predictors and biomarkers of complications and cardiovascular mortality in 
diabetes. A prospective study performed on 315 T2D patients showed that NT-proBNP levels were 
greater in patients with albuminuria. Furthermore, NT-proBNP was a strong predictor of all-cause 
and cardiovascular mortality independent of potential confounding risk factors and had a 
predictive value for all-cause mortality comparable to that of microalbuminuria (1). Consistently, 
we have recently reported that NT-proBNP was strongly and independently associated with 
cardiovascular mortality in a longitudinal study performed on a large cohort of 1,825 T2D patients 
from the population-based Casale Monferrato Study (71), and in the same cohort, NT-proBNP also 
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was a negative confounder in the association between central obesity and cardiovascular death 
(72). Similarly, in type 1 diabetes NT-proBNP is associated with micro- and macrovascular 
complications and is a predictor of cardiovascular mortality (73,74). Recent studies also have 
demonstrated that NT-proBNP predicts cardiovascular events in T2D patients and has a greater 
predictive value than other well-established cardiac risk markers (2,75,76). Collectively, these data 
suggest the possible use of NT-proBNP as a tool for risk stratification, and preliminary data support 
this approach. In the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR 
Controlled Evaluation (ADVANCE) study, NT-proBNP greatly improved the accuracy with which the 
risk of cardiovascular events or death could be estimated in T2D patients and provided much more 
prognostic information than cholesterol or C-reactive protein (77). An additive effect of NT-
proBNP and albuminuria in predicting cardiovascular mortality was, however, observed in the 
Casale Monferrato Study, suggesting that the parallel assessment of both may provide additional 
information for risk assessment (71). 
NT-proBNP and BNP levels also mirror clinically silent processes in the cardiovascular system that 
gradually shift the homeostatic balance from health to disease far before cardiac events occur, 
and they are both markers and predictors of earlier cardiac abnormalities in diabetic patients. In 
the Hoorn Study (3), a slight increase in baseline BNP levels was a strong predictor of both LV 
hypertrophy and diastolic LV dysfunction, and this association was particularly evident in T2D 
patients. In asymptomatic T2D patients, NT-proBNP was associated with silent myocardial 
ischemia independent of microalbuminuria. Furthermore, a 10-year longitudinal study performed 
on asymptomatic high-risk diabetic patients found that NT-proBNP ≥38 pg/mL was the only 
independent predictor of silent coronary artery disease (4). Hypoxia and myocardial wall strain are 
likely inducers of BNP in these settings. In addition, inflammatory cytokines also may be involved 
as both TNF-α and IL-6 induce BNP secretion in cultured cardiomyocytes, their plasma levels rise 
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prior to that of NT-proBNP in hypertensive subjects (78), and the association between NT-proBNP 
and vascular complications was dependent on TNF-α in the EURODIAB study (73). A strategy that 
selects asymptomatic T2D patients, based on BNP and NT-proBNP levels, for further investigation 
(e.g., echocardiography, stress testing) is very attractive. Supporting data are still scarce; however, 
Nadir et al. (79) have recently reported that in a community cohort BNP measurement was an 
optimal screening test to identify individuals with silent cardiac damage for further assessment. In 
addition, NT-proBNP may be proposed as a tool to guide intervention for primary prevention. In 
the Casale Monferrato study (71), NT-proBNP was prospectively associated with cardiovascular 
mortality even in normoalbuminuric patients without CVD at baseline, indicating that NT-proBNP 
may be useful for identification and treatment of patients with a hitherto unknown high risk of 
cardiovascular death. A prospective randomized controlled trial has recently substantiated this 
hypothesis by showing a remarkable 65% reduction in the risk of the primary end point of 
hospitalization or cardiac death in T2D patients with NT-proBNP levels greater than >125 pg/mL 
and no known cardiac disease randomized to a biomarker-guided “intensified” treatment (80). 
Taken together, epidemiological evidence summarized here indicates that BNP and NT-proBNP are 
important biomarkers of CVD complications in patients with diabetes. The “clinical paradox” of 
BNP and NT-proBNP being negative predictors of diabetes and positive predictors of diabetes 
complications is unexplained; however, a possible interpretation is that changes in BNP and NT-
proBNP levels reflect different pathophysiological processes in subjects at risk for diabetes and in 
those at risk for diabetes complications. In obese subjects, reduced BNP and NT-proBNP levels 
may mirror a deficiency in BNP synthesis, contributing to dysmetabolism and diabetes onset. On 
the contrary, in diabetic patients an increase in BNP and NT-proBNP levels may reflect proBNP 
accumulation that masks the linear relationship between residual active BNP and metabolic 
parameters, but being the result of altered cardiac processing is a valuable biomarker of early 
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cardiac and hemodynamic abnormalities and of the inability of the heart to effectively counteract 
them by enhancing active BNP production. In keeping with this scenario, recent data from the 
Multi-Ethnic Study of Atherosclerosis (MESA) (81) have shown that when subclinical CVD develops 
and NT-proBNP levels rise, the inverse relationship between NT-proBNP and both BMI and insulin 
resistance is completely lost. 
Future Perspectives 
In the past decade our understanding of the role of the NP system in diabetes has significantly 
improved; however, many questions still need to be answered. In particular, more research is 
required to clarify the mechanisms of the natriuretic handicap in obesity, the pathogenetic link 
between NP deficiency and diabetes onset, and the regulation of proBNP processing both in the 
heart and the bloodstream. 
Regarding the use of NPs for treatment, preclinical and epidemiological data support the 
hypothesis of a role of ANP and BNP in the development of obesity and diabetes, but it is still 
unknown whether ANP and BNP may be effective in inducing weight loss and preventing diabetes, 
and there are concerns that NP-induced excessive lipid mobilization may promote muscular and 
hepatic ectopic fat storage and, thus, insulin resistance. To address these issues, development of 
appropriate therapeutic tools targeting the NP system and intervention trials in humans is needed 
and some effort has already been made. Studies looking at the effect of chronic NP infusion on 
metabolism are ongoing (82) and long half-life BNP formulations are under development (83). 
Agents that selectively either block NPR-C or activate NPR-A may be even more desirable as NPR-C 
overexpression may reduce the efficacy of BNP infusion. An alternative strategy is to enhance ANP 
and BNP levels by inhibiting the catalytic enzyme NEP. However, NEP degrades other vasoactive 
peptides, such as angiotensin I, bradykinin, and endothelin-1, leading to undesirable 
hemodynamic effects. Combined inhibition of NEP and ACE is not a suitable strategy because of a 
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significant increased risk of angioedema; however, the use of angiotensin receptor blockade with 
NEP inhibition (ARNi) is a potential alternative option (23). In this regard, it is noteworthy that the 
PARADIGM-HF trial, testing efficacy and safety of the ARNi LCZ696 as compared with enalapril in 
patients with HFREF (34% with diabetes), has been stopped early based on evidence of compelling 
efficacy, and these promising incoming results may open the way to future trials in obese and 
diabetic patients. 
Recent studies also suggest ancillary effects on the NP system of drugs currently used for diabetes 
treatment. In mice, liraglutide induces the cardiac release of ANP. If results are confirmed in 
humans, physicians may take advantage of this gut−heart link and use long-acting GLP-1 receptor 
agonists to compensate for NP deficiency and gain indirect beneficial hemodynamic and metabolic 
effects mediated by ANP (45). DPP-4 inhibitors reduce BNP degradation to BNP3–32 (24) and thus 
may enhance full-length BNP bioavailability, potentially resulting in advantageous effects. 
However, the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes 
Mellitus–Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial has unexpectedly shown 
increased rates of hospitalization for HF in diabetic patients treated with saxagliptin. Although 
treatment neither increased nor decreased the composite cardiovascular primary end point, 
further studies are needed to clarify this issue and to rule out the unlikely possibility of a BNP-
related effect (84). 
Finally, the use of more reliable and specific assays for the measurement of both BNP and NT-
proBNP is required. Although poor specificity of current assays may not hamper the clinical value 
of BNP and NT-proBNP as a predictor and biomarker of CVD, it significantly limits our possibility to 
understand underlying pathophysiological mechanisms and to envision novel therapeutic 
strategies. Recently, a new antibody that binds to the cleavage site of proBNP (Hinge76) has been 
developed, allowing accurate proBNP measurement (85). Furthermore, new NT-proBNP assays 
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using antibodies directed against nonglycosylated epitopes are under development to overcome 
the problem of poor reactivity of current assays for O-glycosylated NT-proBNP (25). Whether 
these new assays will result in better clinical applicability awaits further evaluation. 
Conclusions 
Recent studies showing a role of NPs in metabolism and T2D onset have extended the interest of 
NP-related research beyond CVD and raised the possibility that new intervention strategies 
targeting the NP system may be effective in lowering not only blood pressure and sodium 
retention but also body weight and the risk of diabetes. The use of NT-proBNP as a tool for early 
diagnosis, risk assessment, and guided intervention in CVD holds great promise for improving the 
care of patients with diabetes. 
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Figure Legends 
Figure 1 ANP (red), BNP (blue), and CNP (green) NPs are secreted by the heart in response to 
various inducers and bind to high-affinity NPR-A, NPR-B, and NPR-C. NPR-C binds to all three 
peptides with similar affinity, whereas NPR-A and NPR-B differ in ligand specificity (NPR-A: 
ANP>BNP>>CNP; NPR-B: CNP>>ANP≥BNP). Binding to both NPR-A and NPR-B activates particulate 
guanylyl cyclase and increases intracellular cGMP leading to PKG activation. Binding to the 
clearance NPR-C leads to NP internalization and enzymatic degradation. GTP, guanosine-5-
triphosphate. 
Figure 2  Schematic representation of proBNP processing and cross-reactivity of assays measuring 
BNP and NT-proBNP. ProBNP can be posttranslationally O-glycosylated (O-glyc) within the Golgi 
apparatus. Both O-glycosylated and non-O-glycosylated proBNP are cleaved to BNP and NT-
proBNP in equimolar fashion by the enzyme furin and then secreted into the circulation. In the 
bloodstream, BNP can be further degraded to BNP3–32 and other breakdown products (junk-
BNP). ProBNP can be released prior to processing, particularly when O-glycosylated at position 
Thr71 interferes with cleavage by furin, and may undergo processing into the bloodstream. Assays 
measuring BNP also recognized proBNP, BNP3–32, and junk-BNP (black square). Assays measuring 
NT-proBNP cross-react with proBNP (green square) but have poor reactivity for O-glycosylated NT-
proBNP and proBNP (dotted green square). 
Figure 3 Potential link between NPs, obesity, insulin resistance, and diabetes. Obesity and insulin 
resistance are associated with both impaired ANP and BNP cardiac release and overexpression of 
the clearance NPR-C, leading to reduced NP-mediated beneficial effects on target organs of 
metabolism (adipose tissue, skeletal muscle, pancreatic β-cells, central nervous system). This 
results in further weight gain and worsening of insulin resistance and also may favor diabetes 
development. 
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Table 1  
NPs and the risk of T2D in human epidemiological studies 
Study Study design Study population N 
Biomarkers/gene 
variant 
Event 
Adjusted OR/HR 
(95% CI) 
Malmö 
Study (6) 
Prospective study (16-
year follow-up) 
Swedish, no 
history of 
diabetes,
*
 CVD, 
HF 
1,828 MR-ANP, NT-proBNP 
Incident diabetes (301 
events: OGTT) 
MR-ANP, OR 0.85 
(0.73–0.99) per SD; 
NT-proBNP, OR 0.92 
(80–1.06) per SD 
ARIC Study 
(7) 
Prospective study (12-
year follow-up) 
U.S., no history of 
diabetes,
*
 CVD, 
HF, CKD 
7,822 NT-proBNP 
Incident diabetes 
(1,740 events: self-
reported, 
medications) 
4th NT-proBNP 
quartile vs. 1st 
quartile, HR 0.75 
(0.64–0.87) 
FINRISK97 
Study (65) 
Prospective study (10.8-
year follow-up) 
Finnish, no 
history of 
diabetes,
*
 5% 
known CVD 
7,827 NT-proBNP 
Incident diabetes (417 
events: national 
registers) 
NT-proBNP, HR 0.82 
(0.73–0.93) per SD 
Pfister et al. 
(64) 
Case-cohort study nested 
in the EPIC-Norfolk study 
Norfolk, U.K., no 
history of 
diabetes, CVD 
440 cases, 
740 control 
subjects 
NT-proBNP 
T2D (440 cases: self-
reported, 
medications, national 
registers) 
HR 0.79 (0.64–0.97) 
per SD 
Pfister et al. 
(64) 
Mendelian randomization 
study: meta-analysis of 
11 case-control studies 
European descent 
23,382 cases, 
57,898 
control 
subjects 
C allele rs198389 in 
BNP locus 
T2D (23,382 cases) 
OR 0.94 (0.91–0.97) 
per allele 
Malmö 
Study (61) 
Mendelian randomization 
study (14-year follow-up) 
Swedish, no 
history of 
diabetes
**
 
27,307 
One copy of the G 
allele rs5068 in the 
ANP locus 
Incident diabetes 
(2,823 events: 
national registries) 
HR 0.88 (0.78–0.99) 
per allele 
 
CKD, chronic kidney disease; HR, hazard ratio; OGTT, oral glucose tolerance test; OR, odds ratio. 
* Fasting glucose available at baseline. 
** Fasting glucose available in a subgroup. 
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